Skip to main content

Advertisement

SpringerLink
Log in

Screening for new agents

  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

Screening for new antiviral drugs is concentrated on a search for inhibitors of the human immunodeficiency virus, herpesviruses, influenza virus, hepatitis B virus and rhinovirus. The first step in the process is usually the screening of virus-infected cell cultures followed by secondary screening in infected animals. The relevance of the different screening methods for predicting clinical efficacy is at present uncertain due to the low number of compounds evaluated in double-blind placebo-controlled clinical trials. As a consequence of the con-siderable activity in ongoing research on antiviral drugs the predictive value of the screening systems is expected to improve.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Öberg B: Inhibition of virus-specific enzymes. In: Stuart-Harris CH, Oxford J (ed): Problems of antiviral therapy. Academic Press 1983, p. 35–69.

  2. Galasso GJ, Merrigan TC, Buchanan RA: Antiviral agents and viral diseases of man. Raven Press, New York, 1984.

    Google Scholar 

  3. Oxford J, Öberg B: Conquest of viral diseases: a topical review of drugs and vaccines. Elsevier, Amsterdam, 1985.

    Google Scholar 

  4. Hu JM, Hsiung GD: Evaluation of new antiviral agents. I: In vitro perspectives. Antiviral Research 1989, 11: 217–232.

    Google Scholar 

  5. Hsiung GD, Chan VF: Evaluation of new antiviral agents. II: The use of animal models. Antiviral Research 1989, 12: 239–258.

    Google Scholar 

  6. Field HJ, Brown GA: Animal models for antiviral chemotherapy. Antiviral Research 1989, 12: 165–180.

    Google Scholar 

  7. Tyrell DAJ, Al-Nakib W: Prophylaxis and treatment of rhinovirus infections. In: DeClercq E (ed): Clinical use of antiviral drugs. Martinus Nijhoff, 1988, 241–276.

  8. Hayden FG, Cote KM, Douglas RG: Plaque inhibition assay for drug susceptibility testing of influenza viruses. Antimicrobial Agents and Chemotherapy 1981, 17: 865–870.

    Google Scholar 

  9. Aoki FY, Stiver HG, Sitar DS, Boudreault A, Ogilvie RI: Prophylactic amantadine dose and plasma concentration-effect relationships in healthy adults. Clinical Pharmacology and Therapeutics 1985, 37: 128–136.

    Google Scholar 

  10. Gilbert BE, Wilson SZ, Knight V, Couch RB, Quarles TM, Dure L, Hayes N, Willes G: Ribavirin small-particle aerosol treatment of infections caused by influenza virus strains A/Victoria/7/83 (HINI) and B/Texas/1/84. Antimicrobial Agents and Chemotherapy 1985, 27: 309–313.

    Google Scholar 

  11. Öberg B, Johansson NGJ: The relative merits and drawbacks of new nucleoside analogues with clinical potential. Journal of Antimicrobial Chemotherapy 1984, 14, Supplement A: 5–26.

    Google Scholar 

  12. Larsson A, Stenberg K, Ericson AC, Haglund U, Yisak WA, Johansson NGJ, Öberg B, Datema R: Mode of action, toxicity, pharmacokinetics and efficacy of some new antiherpesvirus guanosine analogs related to buciclovir. Antimicrobial Agents and Chemotherapy 1986, 30: 598–605.

    Google Scholar 

  13. O'Brien JJ, Campdis-Richards DM: Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1989, 37: 229–390.

    Google Scholar 

  14. Öberg B: Antiviral effects of phosphonoformate (PFA, foscarnet sodium). Pharmacology and Therapeutics 1989, 40: 213–285.

    Google Scholar 

  15. Kristoffersson A, Ericson AC, Sohl-Åkerlund A, Datema R: Limited efficacy of inhibitors of herpes simplex virus DNA synthesis in murine models of recrudescent disease. Journal of General Virology 1988, 69: 1154–1166.

    Google Scholar 

  16. Harmenberg J, Stenberg K: Antiviral activities of guanosine analogs in guinea pig embryonic fibroblasts. Antimicrobial Agents and Chemotherapy 1988, 32: 1533–1536.

    Google Scholar 

  17. Soike KF, Felsenfeld AD, Gerone PJ: Acyclovir treatment of experimental simian varicella infection in monkeys. Antimicrobial Agents and Chemotherapy 1981, 20: 291–297.

    Google Scholar 

  18. Lake-Bakaar DM, Abele G, Lindborg B, Soike KF, Datema R: Pharmacokinetics and antiviral activity in simian varicella virus-infected monkeys of (R,S)-9-[4-hydroxy-2(hydroxymethyl)butyl] guanine, an antivaricella zoster virus drug. Antimicrobial Agents and Chemotherapy 1988, 1807–1812.

  19. Skolnik PR, Hirsch MS: Therapy and prevention of cytomegalovirus infections. In: DeClercq E (ed): Clinical use of antiviral drugs. Martinus Nijhoff, 1988, p. 159–194.

  20. Öberg B: Antiviral therapy. Journal of Acquired Immunodeficiency Syndromes 1988, 1: 257–266.

    Google Scholar 

  21. Gardner MB, Luciw PA: Animal models of AIDS. FASEB Journal 1989, 3: 2593–2606.

    Google Scholar 

  22. Spertzel RO and the Public Health Service Animal Models Committee: Animal models of human immunodeficiency virus infection. Antiviral Research 1989, 12: 22–230.

    Google Scholar 

  23. McClure HM, Anderson DC, Fultz PN, Ansari AA, Lockwood E, Brodie A: Spectrum of disease in macaque monkeys chronically infected with SIV/SMM. Veterinary Immunology and Immunopathology 1989, 23: 13–24.

    Google Scholar 

  24. Putkonen P, Warstedt K, Thorstensson R, Benthin R, Albert J, Lundgren B, Öberg B, Norrby E, Biberfeld G: Experimental infection of cynomolgus monkeys (Macaca fascicularis) with simian immunodeficiency virus. Journal of Acquired Immunodeficiency Syndromes 1989, 2: 359–365.

    Google Scholar 

  25. Namikawa R, Kaneshima H, Lieberman M, Weissman IL, McCune JM: Infection in the SCID-hu mouse by HIV-1. Science 1988, 242: 1684–1686.

    Google Scholar 

  26. Bazin H, Chattopadhaya J, Datema R, Ericson AC, Gilljam G, Johansson NGJ, Hansen J, Koshida R, Moelling K, Öberg B, Remaud G, Stening G, Vrang L, Wahren B, Wu JC: An analysis of the inhibition of replication of HIV and MuLV by some 3′-blocked pyrimidine analogs. Biochemical Pharmacology 1989, 38: 109–119.

    Google Scholar 

  27. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Schooley RT, Jackson GG, Durack DT, King D: The efficacy of azidothymidine in the treatment of patients with AIDS and AIDS-related complex. New England Journal of Medicine 1987, 317: 185–191.

    Google Scholar 

  28. Lambert JS, Scidlin M, Reichman RC, Plank CS, Laverty M, Morse GD, Knupp C, McLaren C, Pettinelli C, Valentine FT, Dolin R: 2′3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. New England Journal of Medicine 1990, 322: 1333–1340.

    Google Scholar 

  29. Löfgren B, Nordenfelt E, Öberg B: Inhibition of RNA-versus DNA-dependent duck hepatitis B virus DNA polymerase activity by nucleoside and pyrophosphate analogs. Antiviral Research 1989, 12: 301–310.

    Google Scholar 

  30. Sherker AH, Hirota K, Omata M, Okuda K: Foscarnet decreases serum and liver duck hepatitis B virus DNA in chronically infected ducks. Gastroenterology 1986, 91: 818–824.

    Google Scholar 

  31. Nordenfelt E, Löfgren B, Chattopadhaya J, Öberg B: Inhibition of hepatitis B virus DNA polymerase by 3′-azido-3′-deoxythymidine triphosphate but not by its three analogues. Journal of Medical Virology 1987, 22: 231–236.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Virology, Karolinska Institute, S-105 21, Stockholm, Sweden

    B. Öberg

  2. Medivir AB, Lunastigen 7, S-14144, Huddinge, Sweden

    B. Öberg & L. Vrang

Authors
  1. B. Öberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Vrang
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Öberg, B., Vrang, L. Screening for new agents. Eur. J. Clin. Microbiol. Infect. Dis. 9, 466–471 (1990). https://doi.org/10.1007/BF01964285

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01964285

Keywords

Search

Navigation